Answers are grounded in this paper and cite their sources.
Introduction. The quality of life (QoL) became a very important parameter in the XXI century which often decides about the type of treatment. The spectrum of treatment possibilities is constantly expanding due to the rapid technological development. Currently most up-to-date MiniMed 640G system which is able to predict hypoglycemia episode, flexibly and transiently stop insulin delivery before approaching programmed low glucose limit and automatically resume it (SmartGuard technology) can become a way to improve the QoL of diabetic patients. Material and methods. The questionnaire survey was conducted among 10 girls and 14 boys at the age of 2–15 (median 8) years with well-controlled DM1 (HbA 1c varied from 5.8 to 8.8%, mean 6.7%). The mean time from diagnosis was 3.7 years. The main inclusion criteria was the therapy with 640G system. Patients were previously treated with insulin pumps with or without hypoblocade (Paradigm® 722/MiniMed® Veo). 3–11 months after introducing 640G system to therapy during the follow-up visit two surveys were conducted simultaneously: PedsQLTM 3.0 Diabetes which measured the QoL in diabetic patients (Survey I) and the authorial questionnaire (Survey II) which measured the satisfaction of 640G therapy (consisted of 11 questions, 2 closed and 9 semi-closed-ended). Results. Considering participants’ answers in Survey I, the mean scores of QoL regarding communication (79%), concerns (60%), treatment (76%) and diabetes (69%) which according to our scale (0–19% no impact, 20–39% low impact, 40–59% moderate impact, 60–79% high impact, 80–100% very high impact) proved that QoL was perceived high. The results of Survey II showed gladness and assurance of the patients with 640G therapy. Relying on their self-observation, over a half of participants (17 people) certified a serious reduction of both hypo/hyperglycemia episodes. 8 patients/caregivers highlighted a great coherence between blood glucose measured by sensor and glucose meter which enabled them to decrease the frequency of pricking fingers. 11 patients considered management of DM1 to be easier, they also noticed better cooperation with 640G system. Conclusion. Patients with DM1 using 640G system are satisfied with the effects of the therapy, they feel safer and their QoL measured by PedsQL is relatively high.
No takes yet. Share an insight, caveat, or question.
Tabor et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: